{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:31:12Z","timestamp":1772166672996,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"ILKO pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00803-0","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:03:02Z","timestamp":1729674182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bioequivalence study of eltrombopag 75\u00a0mg film-coated tablets under fasting conditions during the Covid-19 pandemic in healthy Caucasian male subjects"],"prefix":"10.1186","volume":"25","author":[{"given":"Ahmet","family":"Inal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Pinarbasli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burcu","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Reinsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mumtaz M.","family":"Mazicioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma Alime","family":"Koru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"28","key":"803_CR1","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1200\/JCO.22.02699","volume":"41","author":"EN Oliva","year":"2023","unstructured":"Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A. Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: \u0131nterim results of a phase II, randomized, placebo-controlled clinical trial (EQOL-MDS). J Clin Oncol. 2023;41(28):4486\u201396.","journal-title":"J Clin Oncol"},{"key":"803_CR2","unstructured":"Revolade International non-proprietary name: eltrombopag\/eltrombopag olamine 17 December 2015 EMA\/CHMP\/38474\/2016. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/revolade-h-c-1110-ii-0023-epar-assessment-report-variation_en.pdf. Accessed 25 July 2024."},{"key":"803_CR3","unstructured":"PROMACTA-eltrombopag olamine tablet, film coated highlights of prescribing information. https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=7714a0ed-34bb-46e6-a0a5-b363908b22c2%26version=21. Accessed 25 July 2024."},{"issue":"7","key":"803_CR4","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2165\/00003495-200868070-00002","volume":"68","author":"R Stasi","year":"2008","unstructured":"Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs. 2008;68(7):901\u201312.","journal-title":"Drugs"},{"key":"803_CR5","unstructured":"PROMACTA\u00ae (eltrombopag) tablets, for oral use highlights of prescribing information. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/promacta.pdf. Accessed 25 July 2024."},{"issue":"4","key":"803_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","volume":"31","author":"DD Williams","year":"2009","unstructured":"Williams DD, Peng B, Bailey CK, Wire MB, Deng Y, Park JW, Collins DA, Kapsi SG, Jenkins JM. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764\u201376.","journal-title":"Clin Ther"},{"key":"803_CR7","unstructured":"Alvaiz Generic Name: eltrombopag tablets. https:\/\/www.rxlist.com\/alvaiz-drug.htm. Accessed 25 July 2024."},{"key":"803_CR8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40265-016-0581-4","volume":"76","author":"CB Burness","year":"2016","unstructured":"Burness CB, Gillian MK, Garnock-Jones KP. Eltrombopag: a review in Paediatric Chronic Immune Thrombocytopenia. Drugs. 2016;76:869\u201378.","journal-title":"Drugs"},{"key":"803_CR9","doi-asserted-by":"crossref","unstructured":"S\u00f6zer G, Inal A, Sezer Z, Martin W, Ottmann E, Reinsch M, Koru SA. Bioequivalence study of capsules versus film tablets containing rivaroxaban in healthy Caucasian subjects under fasting and fed conditions. Clin Pharmacologyin Drug Dev. 2024;13(3):281\u20137.","DOI":"10.1002\/cpdd.1342"},{"issue":"4","key":"803_CR10","doi-asserted-by":"publisher","first-page":"e1253","DOI":"10.1002\/prp2.1253","volume":"12","author":"A Inal","year":"2024","unstructured":"Inal A, Sezer Z, Ulu\u00f6zl\u00fc B, Oflas M, Reinsch M, Martin W, Mazicioglu MM, Koru SA. Bioequivalence study of low dose drospirenone\/ethinyl estradiol 3\u00a0mg\/0.03\u00a0mg film tablets under fasting conditions in Turkish healthy female subjects. Pharmacol Res Perspect. 2024;12(4):e1253.","journal-title":"Pharmacol Res Perspect"},{"key":"803_CR11","unstructured":"Pharmaceutical and medical preparations law; No: 1262. Publication date in the official gazette: 26th May, 1928 Issue No. 898. https:\/\/titck.gov.tr\/storage\/legislation\/meFOxeFD.pdf"},{"key":"803_CR12","unstructured":"GCP regulations. Turkish pharmaceuticals and medical devices agency, 13 Nov 2015. https:\/\/titck.gov.tr\/storage\/Archive\/2020\/legislation\/KADKLVZ01IKU13.11.2015Rev08_13ac0133-274b-44dc-98cd-33998758cc72.pdf."},{"key":"803_CR13","unstructured":"Guideline on the investigation of bioequivalence Committee for Medicinal Products for Human Use (CHMP) CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/Corr**, London, 20 Jan 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 25 July 2024."},{"key":"803_CR14","unstructured":"Guideline on bioanalytical method validation EMEA\/CHMP\/EWP\/192217\/2009. 21 July 2011. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-methodvalidation_en.pdf. Accessed 25 July 2024."},{"key":"803_CR15","unstructured":"Guidance for Industry Bioanalytical Method Validation U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). May 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 28 July 2024."},{"key":"803_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.yrtph.2012.08.001","volume":"64","author":"T Grabowski","year":"2012","unstructured":"Grabowski T, Marczak M, Jaroszewski JJ, Whitmire M. Comparison of bioequivalence study regulatory requirements for human and veterinary drugs. Regul Toxicol Pharmacol. 2012;64:233\u201342.","journal-title":"Regul Toxicol Pharmacol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00803-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:04:43Z","timestamp":1729674283000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00803-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00803-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4950508\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by an independent ethics committee-Ethics Committee for Bioavailability-Bioequivalence Trials of Erciyes University (date of approval: 15.06.2022; vote no: 2022\/148) and the Turkish Medicines and Medical Devices Agency (T\u0130TCK) of Turkish Ministry of Health, (date of approval: 01.07.2022, note no.: E-66175679-514.06.01-803603). The purpose of the investigation was fully disclosed to each subject in a written document and oral presentation by the principal investigator or one of the co-investigators. Then, each participant voluntarily signed the informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}